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Disruption of protein homeostasis is an
important feature of many neurode-
generative diseases. The E1 ubiqui-
tin-activating enzyme UBA1 sits at
the apex of ubiquitin pathways, playing
a critical role in regulating protein
homeostasis. UBA1 regulates a
diverse range of cellular processes in
the nervous system.
UBA1 contributes to the pathogenesis
of several neurodegenerative diseases,
including SMA and HD. In SMA,Review
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Neurodegenerative diseases are a leading cause of disability and early death. A
common feature of these conditions is disruption of protein homeostasis.
Ubiquitin-like modiﬁer activating enzyme 1 (UBA1), the E1 ubiquitin-activating
enzyme, sits at the apex of the ubiquitin cascade and represents an important
regulator of cellular protein homeostasis. Critical contributions of UBA1-depen-
dent pathways to the regulation of homeostasis and degeneration in the nervous
system are emerging, including speciﬁc disruption of UBA1 in spinal muscular
atrophy (SMA) and Huntington's disease (HD). In this review we discuss recent
ﬁndings that put UBA1 at the centre of cellular homeostasis and neurodegen-
eration, highlighting the potential for UBA1 to act as a promising therapeutic
target for a range of neurodegenerative diseases.decreased UBA1 expression leads to
perturbations in ubiquitin homeostasis,
aberrant accumulation of downstream
target proteins, and neuromuscular
degeneration. In HD, UBA1 expression
decreases over time, leading to selec-
tive accumulation of toxic forms of hun-
tingtin protein in the brain.
UBA1 represents a novel and promis-
ing therapeutic target for the treatment
of neurodegenerative diseases.
1Euan MacDonald Centre for Motor
Neurone Disease Research, University
of Edinburgh, Edinburgh, UK
2Centre for Integrative Physiology,
University of Edinburgh, Edinburgh,
UK
*Correspondence:
t.gillingwater@ed.ac.uk
(T.H. Gillingwater).Disruption of Protein Homeostasis in Neurodegenerative Disease
Neurodegenerative diseases are a common cause of disability and early death throughout global
populations [1,2]. Although our understanding of the underlying pathogenic mechanisms has
improved greatly over recent years, most neurodegenerative diseases currently remain untreat-
able and incurable. Considerable research efforts are therefore seeking new therapeutic targets
capable of delaying or halting progression of these conditions. Although some neurodegenera-
tive diseases have a simple monogenetic origin, a combination of sporadic and familial forms is
far more common, generating considerable challenges for therapy development [3].
In contrast to the complex interplay of genetic and environmental factors underlying most
neurodegenerative diseases affecting the human population [4], many of these conditions share
a common molecular signature: disruption of protein homeostasis [5]. This often manifests as an
accumulation of ubiquitylated proteins, with evidence for a robust contribution to disease
pathogenesis in conditions such as Parkinson's disease (PD) (see Glossary), Alzheimer's
disease (AD), Huntington's disease (HD), and amyotrophic lateral sclerosis (ALS) [6–9].
Importantly, disruption of protein homeostasis can also occur without aggregation of proteins,
as illustrated in the case of spinal muscular atrophy (SMA) [10,11].
Correct protein degradation is required to maintain cellular homeostasis in all cells and tissues,
including the nervous system, and is regulated by two main pathways: the ubiquitin–proteasome
system (UPS) and autophagy. The UPS identiﬁes and marks proteins for degradation by
covalent binding of ubiquitin to one or more lysine residues of a target protein [12]. This reaction
is mediated by an E1–E2–E3 enzymatic cascade that is similar for ubiquitin and other ubiquitin-
like proteins (UBLs) such as NEDD8, SUMO, and IGS15 (Box 1) [13]. In addition, ubiquitylation of
target proteins can regulate protein localization and function, independent of degradation [12].
Autophagy is a broad term used to describe the degradation of cytoplasmic components622 Trends in Molecular Medicine, October 2015, Vol. 21, No. 10 http://dx.doi.org/10.1016/j.molmed.2015.08.003
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Glossary
Alzheimer's disease (AD): a
neurodegenerative disease
characterized by the extensive loss of
neurons and synapses throughout
the cortex and in certain subcortical
regions and prominent
neuropathology comprising beta-
amyloid- (amyloid plaques) and tau-
(neuroﬁbrillary tangles) positive protein
aggregates. The cause of AD is
complex and is thought to involve
genetic as well as environmental risk
factors.
Amyotrophic lateral sclerosis
(ALS): a neurodegenerative disease
characterized by the degeneration of
upper and lower motor neurons and
the presence of polyubiquitylated,
TDP43-positive protein aggregates.
Mutations across a range of genes
have been shown to cause ALS,
although the vast majority of ALS
patients have a sporadic form of the
disease that is complex and thought
to involve a combination of genetic
and environmental risk factors.
Areﬂexia: the absence of normal
reﬂexes.
(Congenital) contractures: the
presence at birth of contracted or
abnormally short muscles.
Huntington's disease (HD): a
neurodegenerative disease
characterized by the degeneration of
striatal neurons and caused by a
polyglutamine (polyQ) repeat
expansion in the gene encoding
huntingtin (HTT). Pathologically, HD is
characterized by intraneuronal and
intranuclear inclusion bodies that are
positive for mutant HTT protein and,
often, ubiquitin.
Hypotonia: low resistance to stretch
or amount of tension in muscles,
often related to reduced muscle
strength.
Lewy body: eosinophilic,
cytoplasmic protein aggregates found
in several neurological diseases
including PD and Lewy body
dementia.
Parkinson's disease (PD): a
neurodegenerative disease
characterized by the degeneration of
neurons in the substantia nigra and
the presence of Lewy body and
alpha-synuclein pathology. Several
genetic forms of PD exist but most
cases are idiopathic.
Slow Wallerian degeneration
(Wlds) phenotype: a spontaneous
mutation in mice leading to
expression of a protein linking the N-
Box 1. The E1–E2–E3 Ubiquitin Activation Pathway
Ubiquitin is transferred to its target proteins by an enzymatic cascade that involves three types of enzyme and is similar for
ubiquitin and UBLs such as NEDD8, SUMO, and ISG15 as well as the two ubiquitin-like autophagy activation pathways
(Figure I). The main initiator of the activation, conjugation, and ligation of ubiquitin to target protein substrates is the E1
ubiquitin-activating enzyme UBA1. In the ﬁrst step of ubiquitin activation, one of the acetylation domains of UBA1 binds
ubiquitin, ATP, and Mg2+ while the other acetylation domain is used to stabilize this complex [78]. The C terminus of
ubiquitin is acyl-adenylated, allowing the reactive cysteine residue of UBA1 to attack this bond and produce a thioester
link between UBA1 and ubiquitin. In a second ATP- and Mg2+-dependent reaction, UBA1 adenylates a second ubiquitin
molecule, which leads to double loading of UBA1 with two ubiquitin molecules [80]. The double loading of UBA1 with two
ubiquitin molecules enables the transfer of ubiquitin to E2-conjugating enzymes by providing a favorable conformation of
the UBA1–ubiquitin complex [13]. The activated ubiquitin is subsequently transferred to one of 40 E2 enzymes, in a
reaction where E1 and E2 enzymes physically interact to generate a similar thioester reaction. The E2–ubiquitin complex
and the protein targeted for ubiquitylation are subsequently brought together by E3 ligases. E3 enzymes facilitate the
transfer of activated ubiquitin from the E2 enzyme to the target protein. Moreover, a subtype of E3 ligases (HECT domain
E3 ligases) bind ubiquitin through a reactive cysteine residue in their HECT domain and thus transfer ubiquitin to their
protein substrate directly [81]. Hundreds of E3 enzymes exist and it is this step that provides speciﬁcity to the ubiquitin
conjugation reaction [74]. The cycle of E1 activation and transfer of ubiquitin to E2 enzymes can be repeated leading to
polyubiquitylation of substrate proteins, either through linking ubiquitin to one of the seven Lys residues or the initiating
Met residue in ubiquitin itself (creating polyubiquitin chains) or by conjugating ubiquitin onto another Lys residue in the
substrate protein. The site of protein ubiquitylation and the Lys residue at which polyubiquitin chains are formed are
important determinants of the fate of the protein substrate being (poly)ubiquitylated [82].
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Figure I. Simpliﬁed Representation
of the E1–E2–E3 Ubiquitin Activa-
tion Pathway. In an ATP- and Mg2
+-dependent reaction, ubiquitin-like
modiﬁer activating enzyme 1 (UBA1)
activates ubiquitin and transfers it to
one of 40 E2 conjugating enzymes.
Subsequently, one of hundreds of E3
ligases facilitates the transfer of ubiqui-
tin from the E2 enzyme to speciﬁcally
mono- or polyubiquitylate a protein
substrate. In addition, HECT E3 ligases
are able to directly bind ubiquitin and
thereby directly ubiquitylate protein
substrates.including proteins and organelles by lysosomes [14]. Cytoplasmic components are targeted for
degradation by autophagic pathways by an E1–E2–E3 enzymatic cascade that is similar to that
for ubiquitin [15]. Mutations in members of both pathways have been associated with several
neurodegenerative diseases. These include mutations in the E3 ligase PARKIN and the deu-
biquitinating enzyme UCHL1, which are both associated with PD [16,17], and mutations in the
autophagy receptor SQSTM1 (p62) and UBQLN2 (which has been implicated in both the UPS
and autophagy), which are associated with ALS [18,19]. Similarly, loss of autophagy machinery
or proteasome subunits in the nervous system leads to complex neurodegenerative phenotypes
[20–22].
Whereas 40 E2-conjugating enzymes and hundreds of E3 ubiquitin ligases exist, mammalian
cells express only two E1 ubiquitin-activating enzymes [13,23]. Because many degenerative
diseases have been associated with distinct disease proteins, research targeting the UPS in
these diseases has mainly focused on the more substrate-speciﬁc E2 and E3 enzymes [24].
Recent work, however, has speciﬁcally implicated the main upstream E1 ubiquitin-activating
enzyme (UBA1) in a range of neurodegenerative diseases [10,11,25], suggesting a central role
for UBA1 in the regulation of neurodegeneration. In this review we provide an overview of the
canonical role of UBA1 in ubiquitin homeostasis and discuss how altered UBA1 function disrupts
a range of core cellular and neuronal processes, including those affected in neurodegeneration.Trends in Molecular Medicine, October 2015, Vol. 21, No. 10 623
terminal part of Ube4b to Nmnat1.
This fusion protein provides
substantial protection against
Wallerian degeneration and this
mouse model has therefore been
used extensively to study
neurodegeneration and
neuroprotection in vivo.
Spinal muscular atrophy (SMA): a
childhood-onset neurodegenerative
disease characterized by the
degeneration of lower motor neurons;
>95% of SMA cases are caused by
homozygous deletion of the survival
motor neuron 1 (SMN1) gene.These observations lead us to propose a model whereby UBA1 represents a novel and
promising therapeutic target for neurodegenerative disorders.
UBA1 as a Key Regulator of Protein Homeostasis
The range of neurodegenerative diseases characterized by changes in protein homeostasis
illustrates just how vital these pathways are for maintaining a healthy nervous system. Main-
taining protein homeostasis requires correct tagging of target proteins with ubiquitin. The ﬁrst
step in achieving this involves the activation of ubiquitin by UBA1 (Box 1). UBA1 is a highly
conserved protein that is expressed in two main isoforms of 1058 (UBA1a) and 1018 (UBA1b)
amino acids. Expression of UBA1 is essential, as deletion of the UBA1 gene has been shown to
be lethal [26,27]. Although the FAT10-activating E1 enzyme UBA6 has also been shown to be
capable of activating ubiquitin [28–30], the very high expression of UBA1 suggests that ubiquitin
pathways do not depend on activation by UBA6 [29]. This puts UBA1 ﬁrmly at the center of the
regulation of protein homeostasis.
In addition to activating and transferring ubiquitin, UBA1 can also activate and transfer the UBL
NEDD8 under stress conditions (speciﬁcally, when cellular ubiquitin levels are low), which can
lead to a mixture of NEDD8 and ubiquitin being conjugated to protein substrates [31]. In addition,
it has been shown that UBA1 can be required for Atg8-dependent autophagy, although not
through direct activation of the autophagy-associated UBL Atg8 [32]. In this case, UBA1 activity
bypasses the E1 and E2 enzymes Atg7 and Atg3 that are normally required for autophagy,
which suggests that, at least in certain tissues, crosstalk between UBA1 and autophagy
pathways is possible. As described above, the E1 enzyme UBA6 is also capable of activating
ubiquitin [29]. However, in contrast to UBA1, UBA6 is able to activate both ubiquitin and the UBL
FAT10, but has so far been shown to be associated with only one speciﬁc E2 enzyme, USE1.
This suggests that UBA6-mediated ubiquitin activation might be required for ubiquitylation of
(a subset of) speciﬁc proteins rather than playing a central role in protein homeostasis [29]. For
example, brain-speciﬁc depletion of UBA6 expression in mice leads to a range of neuro-
developmental and behavioral defects associated speciﬁcally with elevated levels of the E3
ligase Ube3a and decreased expression of known downstream targets [33]. Also, it has been
shown that proteasomal degradation of UBA1 itself is regulated by UBA6 and USE1-mediated
activation and conjugation of FAT10 to UBA1 [34]. These studies demonstrate that considerable
crosstalk exists between different E1 pathways and reveal that the regulation of these processes
and enzymes is more complex than previously thought.
The combination of activation and conjugation of ubiquitin and UBLs by multiple E1, E2, and E3
enzymes provides cells with practically limitless possibilities for ﬁne-tuning the targeting of
protein substrates toward speciﬁc cellular pathways and fates. Importantly, it also suggests
an even broader role for UBA1 in ubiquitin and UBL activation and implicates UBA1 in the
regulation of a wide range of cellular processes.
Early work investigating the cellular functions of UBA1 established it as an important regulator of
cell cycle progression. Ubiquitylation and deubiquitylation of key cell cycle proteins, including
histone H2A and p53, by numerous enzymes, including UBA1, is essential for cells to progress
through the phases of the cell cycle [35–37] and therefore complete loss of UBA1 function has
detrimental effects on cell cycle progression. Temperature-sensitive mutations revealed how
loss of UBA1 function leads to an overall reduction in the levels of ubiquitylated proteins and
protein degradation, causing cell cycle arrest [38,39]. Pharmacological inhibition of UBA1
prevented UPS-mediated degradation of the tumor suppressor protein p53, inhibiting progres-
sion through the cell cycle [35,36]. This requirement for UBA1 is further illustrated by its
subcellular localization, which is intimately related to cell cycle progression. During G1 and
G2 phase, UBA1 is almost exclusively nuclear, whereas in other mitotic phases it is present in624 Trends in Molecular Medicine, October 2015, Vol. 21, No. 10
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Figure 1. Domains of Ubiquitin-Like Modiﬁer Activating Enzyme 1 (UBA1) and Genetic Variants Identiﬁed in X-
Linked Spinal Muscular Atrophy (XL-SMA). The N-terminal half of UBA1 comprises an inactive adenylation domain
(IAD) that surrounds the ﬁrst catalytic cysteine half-domain (FCCD). The C-terminal half of UBA1 comprises an active
adenylation domain (AAD) that surrounds the second catalytic cysteine half-domain (SCCD). The SCCD contains the
reactive Cys residue that binds ubiquitin. The C-terminal ubiquitin fold domain (UFD) allows UBA1 to bind to E2 enzymes.
When UBA1 is folded into its 3D structure, the FCCH and SCCH and the IAD and AAD are directly adjacent to each other
[78,79] (Box 1). The Met residue at position 40 provides an alternative translational start site that leads to the expression of
the UBA1b isoform of the protein. The UBA1a isoform-speciﬁc N-terminal sequence contains a nuclear localization signal
(NLS) and Ser residues that can be phosphorylated (P residues). Mutations in UBA1 that have been shown to cause XL-
SMA cluster in exon 15 of the protein. The domain structure in this ﬁgure is based on yeast [78] and mouse [79] UBA1
structural analysis. The speciﬁc amino acid positions in the ﬁgure are based on the mouse UBA1 sequence, as the mouse
and human UBA1 protein sequences are more than 95% identical. The amino acids that are mutated in XL-SMA as well as
the amino acid sequences that surround the borders of the various domains are all perfectly conserved between mouse and
human UBA1 sequences.both the nucleus and the cytoplasm [40]. How changes in the subcellular localization of UBA1
are functionally related to cell cycle progression remains to be further investigated.
UBA1 can be phosphorylated at several serine residues [41], again closely linked to cell cycle
status; UBA1 phosphorylation is maximal during G2 phase [42]. Phosphorylation and nuclear
localization are also related to the expression of the isoforms of UBA1, UBA1a and UBA1b.
These isoforms differ in their translational start site, leading to an additional N-terminal 40 amino
acids in UBA1a [42]. The ﬁrst 11 amino acids of UBA1a (absent in UBA1b) contain a nuclear
localization signal (NLS) and four serine residues essential for phosphorylation and nuclear
localization (Figure 1). Non-phosphorylated UBA1a can still localize to the nucleus, but the NLS is
required for efﬁcient phosphorylation [42]. Interestingly, reduced phosphorylation of UBA1a in
macrophages was shown to attenuate nucleotide excision repair deﬁciencies in terminally
differentiated macrophages [43]. In addition, UBA1 was shown to be essential for protein
ubiquitylation-mediated repair of double-strand DNA breaks [44]. These ﬁndings illustrate that
UBA1 is also implicated in DNA repair pathways.
UBA1 is Essential for Maintaining Neuronal Homeostasis
In neurons, local regulation of protein translation and degradation (including at distal cellular
sites such as the synapse) is required for normal cellular function. The important contribution
of the UPS to these pathways has been demonstrated for many different aspects of pre- and
postsynaptic form and function, including growth cone guidance and synaptic transmission
(see, for example, [45,46]). As UBA1 represents the initiating apex of UPS pathways in
neurons, UBA1 is at the center of a range of cellular and molecular pathways required for theTrends in Molecular Medicine, October 2015, Vol. 21, No. 10 625
development and maintenance of a healthy nervous system. It is perhaps unsurprising,
therefore, that disruption of UBA1 in neurons leads to compromised neuronal form and
function. For example, inhibition of UBA1 leads to increased miniature and spontaneous
synaptic currents at both excitatory and inhibitory synapses in cultured hippocampal neu-
rons [47]. Likewise, UBA1 is required for axon development in Drosophila, where loss of
UBA1 leads to pruning defects [48]. Interestingly, increased levels of UBA1 have also been
associated with the slow Wallerian degeneration (Wlds) phenotype [49,50].
The studies discussed above reveal an important role for UBA1 in the regulation of numerous
core cellular and molecular pathways highly relevant to neurons, including cell cycle
status, developmental axon pruning, and neurotransmitter release. The range of cellular
pathways implicated in UBA1 dysfunction therefore raises the strong likelihood that disrup-
tion of UBA1 levels and/or function contributes to pathological changes in the nervous
system occurring during neurodegeneration. Importantly, several lines of evidence suggest
that the timing and severity of UBA1 perturbations are likely to dictate the resulting phe-
notype. For example, studies in Drosophila have shown that partial loss of UBA1 leads to
defects in apoptosis [51,52] whereas complete loss of UBA1 leads to cell cycle arrest [51]
and tissue overgrowth in a non-cell autonomous manner [51,52]. Moreover, in Caenorhab-
ditis elegans loss of UBA1 function at different developmental stages leads to a range of
phenotypes including embryonic or larval lethality, decreased fertility in adult stages, and
late-onset paralysis [26].
UBA1 and the Regulation of Neurodegeneration
The importance of UBA1 for the maintenance of neuronal health and function has triggered
considerable research efforts aiming to speciﬁcally investigate the extent to which this critical
ubiquitylation enzyme contributes to neurodegenerative disease. Initial work with Drosophila
models has shown that mutations associated with modest impairment of UBA1 function and
expression [52] lead to a phenotype reminiscent of neurodegenerative disease. Flies that are
homozygous for a UBA1 allele that represents a partial loss of function are characterized by a
marked decrease in lifespan and severe locomotion deﬁcits [53].
Speciﬁc links between UBA1 and neurodegenerative diseases affecting the human population
have recently been established, with strong clinical and experimental data highlighting roles for
UBA1 in SMA. Mutations in UBA1 cause a rare form of SMA known as X-linked SMA (XL-SMA), a
disease that is clinically similar to SMA but not caused by homozygous deletion of the SMN1
gene [10,54,55]. Clinically, XL-SMA is characterized by muscle weakness associated with
anterior horn motor neuron loss, hypotonia, and areﬂexia. Moreover, in contrast to SMA,
XL-SMA is typically associated with congenital contractures and fractures [10,54,55]. Path-
ologically, widespread sensory and cerebellar abnormalities have been described, although the
thalamic pathology that is often observed in SMN1-dependent SMA was absent [54]. Interest-
ingly, all mutations that have so far been identiﬁed in XL-SMA cluster in exon 15 of the UBA1
gene (Figure 1). How these mutations lead to neurodegeneration is currently unknown, but it is
likely that they are associated with impairment of UBA1 function, possibly due to altered
methylation patterns of exon 15 [10].
Although XL-SMA represents a very rare form of SMA, recent work has demonstrated that UBA1
may also play an important role in the pathogenesis of more common, SMN1-dependent forms
of the disease. Suppression of full-length survival motor neuron protein (SMN) was found to lead
to widespread disruption of protein homeostasis in SMA mouse models, including a robust drop
in levels of UBA1 protein [11]. Investigation of the molecular mechanisms linking SMN depletion
with the regulation of UBA1 protein levels suggested a complex interaction involving multiple
potential routes, including modiﬁcations in the splicing of UBA1 and direct protein–protein626 Trends in Molecular Medicine, October 2015, Vol. 21, No. 10
interactions between UBA1 and SMN [11]. Experiments utilizing zebraﬁsh revealed that repli-
cating this suppression of UBA1 in vivo was sufﬁcient to phenocopy the motor neuron axon
defects observed in SMA-model zebraﬁsh [11]. This supports the ﬁnding from earlier studies
utilizing Drosophila, described above, which showed that targeting UBA1 was sufﬁcient to
generate a pronounced motor behavior phenotype and decrease survival [53]. Given that there is
a growing body of evidence suggesting that the most severe forms of SMA involve pathological
changes in a range of cells and tissues within and beyond the neuromuscular system [56], it was
perhaps unsurprising that UBA1 defects were also identiﬁed across a broad range of body
organs in SMA mice [11]. The contribution of UBA1 to SMA pathogenesis has even been
demonstrated at the level of single cell types, where myelination defects in peripheral nerves [57]
were found to occur due to reduced levels of UBA1 in Schwann cells [58].
Although UBA1 is strongly linked to the pathogenesis of SMA, recent ﬁndings suggest that its
inﬂuence on neurodegeneration pathways extends beyond this condition. For example, it has
been demonstrated that UBA1 acts as an important modiﬁer of polyglutamine (polyQ) protein
toxicity in a mouse model of HD [25]. Inhibition of UBA1 led to an increase in levels of mutant
protein aggregates and with increasing age expression of UBA1 was found to decline. These
ﬁndings suggest that decreased ability of UBA1 to degrade mutant protein correlates with
increased accumulation of mutant protein species in affected tissues over time [25], identifying a
potential role for UBA1 in neurodegenerative diseases that are characterized by their late onset.
In addition, UBA1 knockdown has been shown to increase HD-associated polyQ protein
aggregation in an siRNA screen in C. elegans [59]. Thus, UBA1 appears to have the capacity
to inﬂuence neurodegeneration in conditions manifesting primarily in the early stages of life (SMA)
as well as those that are associated with advancing age (HD).
Alongside these direct links between UBA1 and SMA/HD, indirect evidence from protein-
interaction and -modiﬁer studies provides further experimental support indicating a potentially
important role for UBA1 in regulating neurodegeneration pathways relevant to a broad range of
diseases. For example, UBA1 modiﬁes the toxicity of a speciﬁc Tau genetic mutant in Drosophila
[60]. When interacting proteins of the ALS-associated protein FUS were studied, UBA1 was
identiﬁed as preferentially binding to and interacting with an ALS-causing FUS mutant but not
wild-type FUS [61]. Moreover, exposure of mouse and rat models to pesticides implicated in
idiopathic PD has been shown to lead to increased expression of the PD disease protein alpha-
synuclein as well as selective damage to dopaminergic neurons and locomotion defects [62,63]
that are speciﬁcally associated with UBA1 but not proteasome inhibition [64]. Finally, in the
cytosolic fraction of AD brain samples, the expression and activity of UBA1 was strongly reduced
[65].
Taken together, the studies discussed above provide experimental evidence linking altered
levels or activity of UBA1 with pathogenic events underlying a range of neurodegenerative
diseases, including HD, PD, ALS, and SMA. This places UBA1 at the center of a molecular ‘hub’
capable of modulating neurodegenerative pathways in the nervous system triggered by a
diverse range of genetic defects and/or environmental factors (Figure 2, Key Figure). However,
this model raises something of a quandary: how can changes in the levels and/or activity of a
ubiquitously expressed core E1 enzyme contribute to neurodegenerative conditions where,
more often than not, speciﬁc cell types are susceptible (e.g., lower motor neurons in SMA, striatal
neurons in HD)? Mutations in the UBA1 gene in humans disrupt UBA1 levels and function
throughout all cells and tissues of the body but manifest as an early-onset neurodegenerative
disease where lower motor neurons are particularly affected (XL-SMA) [10,54,55]. This is
consistent with ﬁndings in Drosophila, where motor neurons appear to be particularly sensitive
to perturbations in UBA1 [53]. This suggests that motor neurons (particularly large neurons with
a requirement to support very long axonal processes and distal synaptic terminals) areTrends in Molecular Medicine, October 2015, Vol. 21, No. 10 627
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Figure 2. In spinal muscular atrophy
(SMA), UBA1 levels are suppressed
throughout the neuromuscular system
and decrease further as the disease pro-
gresses. In combination with low levels of
full-length survival motor neuron protein
(SMN) (due to deletion of one copy of
SMN1), this leads to motor neuron degen-
eration as well as a range of systemic
pathologies. In Huntington's disease
(HD), UBA1 activity as well as expression
decreases with advancing age in a tissue-
speciﬁc manner. This inﬂuences the
aggregation of mutant huntingtin (HTT)
protein, speciﬁcally in the brain and neu-
ronal nuclei, which is associated with neu-
ronal degradation. In other late-onset
neurodegenerative disorders such as Par-
kinson's disease (PD), Alzheimer's dis-
ease (AD), and amyotrophic lateral
sclerosis (ALS), UBA1 expression or activ-
ity could also decrease with age for var-
ious reasons (such as mislocalization or
protein sequestering). In combination with
a range of genetic and environmental risk
factors that have been associated with
these diseases, this could also lead to
degeneration of speciﬁc subpopulations
of neurons and/or affect the protein
aggregation that is observed in these
disorders.
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particularly susceptible to perturbations in ubiquitin homeostasis. This model is supported by the
ﬁnding that low levels of SMN protein in SMA lead to suppression of UBA1 protein levels
throughout the body, but again lower motor neurons are the primary pathological target [11], in
agreement with the ‘threshold model’ hypothesis for SMA [66]. For neurodegenerative con-
ditions caused by genetic or environmental factors not associated with global perturbations in
UBA1 levels or function, it is perhaps most likely that targeting of restricted neuronal populations
results from differential susceptibility of neuronal populations to the initial triggering ‘insult’ itself,
with UBA1-dependent pathways subsequently engaged downstream. For conditions where
severe disruption of protein homeostasis results from the formation of protein aggregates, this is
likely to disrupt UBA1-mediated regulation of ubiquitin homeostasis, although the mechanism
underlying this disruption is currently unclear. It is possible that UBA1 localization in neurons is
disrupted, as has been shown in AD patient samples [65]. Moreover, UBA1 might be seques-
tered into disease-associated protein aggregates, as has been shown for Lewy bodies in
models of PD [67]. Finally, as overall UPS function decreases with advancing age [68], UBA1
function might eventually fall below a critical threshold level required to maintain protein
homeostasis, as was illustrated speciﬁcally for polyQ protein aggregation in HD [25].
UBA1 as a Therapeutic Target for Neurodegenerative Disease
The fundamental role played by UBA1 in regulating cellular homeostasis and neurodegeneration
suggests that targeting of UBA1 and/or its downstream pathways may represent a potential
therapeutic approach to slow or halt the progression of several neurodegenerative conditions.
Here we discuss current approaches that have been used to modulate UBA1 and UPS function
and suggest possible future strategies to develop UBA1-based therapies.
The UPS has long been considered an attractive therapeutic target for conditions such as
cancer, as many tumors are known to show aberrant protein ubiquitylation patterns and
disrupted control of cell cycle progression [69]. For example, bortezomib and carﬁlzomib,
both inhibitors of the 26S proteasome, are FDA-approved treatments for multiple myeloma.
Their use illustrates how the targeting of even a nonspeciﬁc part of the UPS can be a safe
and efﬁcient way to treat disease, although not all patients respond to individual treatments
and they may develop resistance over time [70]. UBA1-targeted therapies are also being
developed in this regard, mainly focusing on small-molecule inhibitors of UBA1 (reviewed in
[71]) targeting various aspects of UBA1-mediated ubiquitin activation [72]. It is important to
note, however, that the studies detailed above show a strong link between reduced levels/
activity of UBA1 and neurodegenerative phenotypes. Thus, one potential side effect of
systemic suppression of UBA1 activity for cancer treatment could be an increased risk
of, or susceptibility to, neurodegenerative disease.
In contrast to the development of UBA1 inhibitors for the treatment of cancer, upregulation of
UBA1 levels and/or activity is likely to be required for the treatment of neurodegeneration.
However, this approach has yet to be extensively explored and therapeutic tools remain limited.
Importantly, from a safety perspective, several lines of evidence suggest that high levels of UBA1
are safe and well tolerated. For example, levels of UBA1 are increased by 40–60% in the
nervous system of mice carrying the neuroprotective Wlds mutation [49,50] and these mice
show no overt phenotype (with normal behavior, lifespan, and organ histopathology and no
evidence for increased oncogenic activity). Moreover, UBA1 comprises 2% of the total protein
content of a cell [73,74] and at steady-state levels the UBA1-speciﬁc E2 enzymes CDC34 and
CDC34B are fully charged with ubiquitin, which indicates that there is sufﬁcient active E1 to
maintain ubiquitin-charged E2 enzymes [29]. When sufﬁcient levels of UBA1 are available, the
interaction of E2-ubiquitin with E3 ligases therefore limits the rate of ubiquitylation [29]. This
suggests that cells can tolerate high basal levels of UBA1 and that further upregulation of UBA1
levels may be physiologically tolerable.Trends in Molecular Medicine, October 2015, Vol. 21, No. 10 629
Outstanding Questions
How do disease-speciﬁc genetic and
environmental triggers cause modiﬁca-
tions to UBA1 expression and/or
function?
Are there further disruptions in the
expression of speciﬁc parts of the
UPS downstream of UBA1 (E2, E3
enzymes)?
To what extent does disruption of
UBA1 mediate neurodegeneration in
diseases where only indirect links cur-
rently exist (such as AD, PD)?
What are efﬁcient and safe ways of
elevating UBA1 expression and/or
activity in vivo, and does this provide
a viable novel therapeutic approach for
neurodegenerative diseases?Although therapeutically relevant strategies to increase levels of UBA1 are not currently available,
several approaches may be worthy of consideration. For example, gene therapy-based
approaches could be used to increase UBA1 expression levels in a temporally controlled,
targeted manner. Alternatively, small-molecule screens could be employed to identify com-
pounds capable of increasing UBA1 levels (by modulating transcription/translation or protein
stability) or activity (for example, by providing favorable cellular conditions for UBA1 to activate
ubiquitin). Moreover, targeted inhibition of UBA6-mediated degradation of UBA1 [34] is likely to
be an efﬁcient method to increase UBA1 levels.
As UBA1 depletion leads to a reduction in cellular ubiquitin pools [11], another therapeutic
strategy could be to target the restoration of free ubiquitin levels by increasing the activity of
deubiquitination enzymes (DUBs). When UBA1 is inhibited, the DUB UCHL1 is strongly upre-
gulated [75] and inhibition of UCHL1 aggravates rather than ameliorates disease in a mouse
model of SMA [75]. Moreover, subpopulations of motor neurons in a mouse model of ALS that
are resistant to degeneration are characterized by high levels of UCHL1 expression [76]. This
indicates that increasing activity of speciﬁc DUBs could also be an interesting therapeutic
approach for diseases that are characterized by disruption to protein homeostasis.
Finally, an alternative approach for the development of therapies targeting UBA1-mediated
neurodegeneration is to consider key substrate proteins that become differentially ubiquitylated
downstream of perturbations in UBA1 [77]. One good example of where this approach has
already shown considerable promise is for the treatment of SMA. Depletion of UBA1 in SMA
resulted in decreased overall ubiquitylation, and ultimately accumulation, of beta-catenin protein,
leading to increased beta-catenin signaling activity [11]. Pharmacological inhibition of beta-
catenin robustly suppressed SMN-dependent and UBA1-dependent neuromuscular pathology
in vivo [11], thereby highlighting the therapeutic potential of identifying and then targeting protein
modiﬁcations occurring downstream of UBA1. Similar screens aimed at identifying UBA1-
dependent target proteins in affected cell populations in other neurodegenerative conditions
(e.g., HD, ALS, PD) may therefore also serve to generate novel therapeutic targets and
development strategies.
Concluding Remarks
Neurodegenerative diseases are common and severely disabling conditions that often lead to
premature death. Disruption of protein homeostasis is a common feature of many such diseases
and although further research is required (see Outstanding Questions) increasing evidence
places UBA1 as a central regulator of these pathways. Therapeutic targeting of UBA1, or its
downstream disease-speciﬁc targets, may therefore generate potential new avenues for slowing
or halting disease progression in a broad spectrum of disorders.
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